4 Einträge gefunden

1. Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial

   1. Graeser, Monika
   2. Gluz, Oleg
   3. Biehl, Claudia
   4. Ulbrich-Gebauer, Daniel
   5. Christgen, Matthias
   6. Palatty, Jenci
   7. Kuemmel, Sherko

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

   1. Nitz, Ulrike
   2. Gluz, Oleg
   3. Graeser, Monika
   4. Christgen, Matthias
   5. Kuemmel, Sherko
   6. Grischke, Eva-Maria
   7. Braun, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

   1. Gluz, Oleg
   2. Nitz, Ulrike
   3. Kolberg-Liedtke, Cornelia
   4. Prat, Aleix
   5. Christgen, Matthias
   6. Kuemmel, Sherko
   7. Mohammadian, Mohammad Parsa

   2022 - Forschungsinformationssystem des UKE
4. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

   1. Graeser, Monika
   2. Feuerhake, Friedrich
   3. Gluz, Oleg
   4. Volk, Valery
   5. Hauptmann, Michael
   6. Jozwiak, Katarzyna
   7. Christgen, Matthias

   2021 - Forschungsinformationssystem des UKE - frei zugänglich